Respiratory Virus and Microbiome Initiative

Parasites and Microbes

We develop DNA sequencing and analysis platforms to track the transmission and evolution of respiratory viruses and understand their interactions with other microbes in the human respiratory tract. We create targeted approaches to analyse the genomes of multiple common respiratory viruses (such influenza virus, respiratory syncytial virus, and SARS-CoV-2, the virus that causes COVID-19) from individual diagnostic swabs. In addition, by developing untargeted approaches for sequencing all microbes in a sample, we aim to develop tools to identify new viral threats as part of an early warning system to help prevent future pandemics.

Aims

The Respiratory Virus and Microbiome Initiative aims to establish capabilities for large-scale genomic surveillance of respiratory viruses such as influenza virus and respiratory syncytial virus (RSV), and to survey for as yet unknown pathogens. By establishing standardised approaches for combined sequencing of SARS-CoV-2, and other common respiratory viruses in a single assay and developing pathogen-agnostic sequencing approaches, the Initiative will enable:

  • Generation of knowledge on the transmission and evolution of known respiratory viruses and other pathogens.
  • Discovery of novel respiratory viruses to inform early warning systems for new pandemic threats.
  • Deeper understanding of respiratory microbiome dynamics and how this influences health and infection.
  • Tracking and understanding of antimicrobial resistance in the respiratory tract at a population level.

Revealing co-infections with metagenomics

Co-infection and secondary infections caused by bacterial and fungal pathogens are common in severe respiratory viral infections, including for SARS-CoV-2, RSV, and pandemic influenza. As such, a major area of focus for the Respiratory Virus and Microbiome Initiative is on developing the tools and approaches needed to use shotgun metagenomics for untargeted surveys of the microbial diversity present in respiratory swab samples. These approaches will enable a better understanding of how the respiratory microbiota changes during infection, how this relates to variability in the severity of illness between individuals, and can identify opportunities to intervene earlier to prevent or blunt a respiratory pathogen.

Metagenomics also has the potential to allow tracking of antimicrobial resistance (AMR) in the respiratory microbiome, which will be increasingly important in the years to come as the arsenal of effective antimicrobial dwindles.

About the Respiratory Virus and Microbiome Initiative

The Initiative is uniquely placed to undertake this work:

  • Our team has gained deep experience from undertaking the nationwide genomic surveillance for COVID-19 as part of the COVID-19 Genomics UK (COG-UK) consortium and now in collaboration with the UK Health Security Agency (UKHSA).
  • The Sanger Institute has a long history of developing cutting-edge genomic techniques and innovative sequencing approaches.

Research and development work undertaken by the Respiratory Virus and Microbiome Initiative will both benefit from, and contribute to, the core aims of the Sanger Institute’s Parasites and Microbes programme, and public health.

All data, protocols and methods generated through the Initiative will be made freely and publicly available. Over time the platforms and technologies developed by Initiative will be scaled up and productised through the Sanger Institute’s Genomic Surveillance Unit so that public health partners can adopt them as part of their pathogen genomic surveillance programmes.

Opportunities

There are a range of exciting projects underway in our team. We are always on the lookout for bright, motivated people to join the group so, if you’re interested, please drop Ewan Harrison an email and include your CV.